These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25658400)

  • 1. [Urinary incontinence: what's new in therapy?].
    Becher KF; Sieber CC
    Dtsch Med Wochenschr; 2015 Feb; 140(3):164-7. PubMed ID: 25658400
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravesical therapy options for neurogenic detrusor overactivity.
    Reitz A; Schurch B
    Spinal Cord; 2004 May; 42(5):267-72. PubMed ID: 14758352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Overactive bladder].
    Golsong J
    MMW Fortschr Med; 2013 Apr; 155(6):44. PubMed ID: 23700696
    [No Abstract]   [Full Text] [Related]  

  • 5. [Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
    Boudy AS; Thubert T
    Prog Urol; 2015 Jun; 25(8):497-8. PubMed ID: 25748787
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 7. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results.
    Gobeaux N; Yates DR; Denys P; Even-Schneider A; Richard F; Chartier-Kastler E
    Neurourol Urodyn; 2012 Jun; 31(5):672-6. PubMed ID: 22532256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary incontinence in the elderly].
    Becher K; Sieber C
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1574-6. PubMed ID: 21809244
    [No Abstract]   [Full Text] [Related]  

  • 10. Mirabegron (Myrbetriq) for overactive bladder.
    Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
    [No Abstract]   [Full Text] [Related]  

  • 11. [Not Available].
    Perucchini D; Betschart C; Fink D; Scheiner DA
    Praxis (Bern 1994); 2017 Jan; 106(1):37-44. PubMed ID: 28055318
    [No Abstract]   [Full Text] [Related]  

  • 12. Actual treatment of overactive bladder and urge urinary incontinence.
    Cornu JN
    Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The recalcitrant overactive bladder patient.
    Ghoniem GM
    Geriatrics; 2002 May; 57 Suppl 1():23-9. PubMed ID: 12040600
    [No Abstract]   [Full Text] [Related]  

  • 14. [The place of mirabegron in clinical practice].
    Kasyan GR; Sukhikh SO; Pushkar DY
    Urologiia; 2017 Dec; (6):144-148. PubMed ID: 29376612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug Administration.
    Ladi-Seyedian SS; Sharifi-Rad L; Kajbafzadeh AM
    Urology; 2020 Aug; 142():190-194. PubMed ID: 32437774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of novel therapies for overactive bladder.
    Mayr CA; Shepherd JP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OnabotulinumtoxinA injections in detrusor facilitate self-catheterisation in a patient with paraplegia and bladder outlet dyssynergia.
    Hervé F; Viaene A; Everaert K
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28389505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary incontinence in women].
    Kretschmer A; Grabbert MT; Stief CG; Bauer RM
    MMW Fortschr Med; 2015 Sep; 157(15):48-51. PubMed ID: 26349729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.